期刊
NATURE BIOTECHNOLOGY
卷 36, 期 7, 页码 606-+出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nbt.4153
关键词
-
资金
- US National Institutes of Health (NIH) [HL-74124, HL-125422, HL-065222, F30 HL-127977, T32 GM-007171]
- NIH [GM103403]
- NIH-ORIP HEI [RR029205]
- US Department of Energy (DOE) Office of Science [DE-AC02-06CH11357]
Unfractionated heparin (UFH), the standard anticoagulant for cardiopulmonary bypass (CPB) surgery, carries a risk of post-operative bleeding and is potentially harmful in patients with heparin-induced thrombocytopenia-associated antibodies. To improve the activity of an alternative anticoagulant, the RNA aptamer 11F7t, we solved X-ray crystal structures of the aptamer bound to factor Xa (FXa). The finding that 11F7t did not bind the catalytic site suggested that it could complement small-molecule FXa inhibitors. We demonstrate that combinations of 11F7t and catalytic-site FXa inhibitors enhance anticoagulation in purified reaction mixtures and plasma. Aptamer-drug combinations prevented clot formation as effectively as UFH in human blood circulated in an extracorporeal oxygenator circuit that mimicked CPB, while avoiding side effects of UFH. An antidote could promptly neutralize the anticoagulant effects of both FXa inhibitors. Our results suggest that drugs and aptamers with shared targets can be combined to exert more specific and potent effects than either agent alone.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据